Physician profile
Robert W Cain
NPI 1083672745
$2,251.46
in general payments reported to CMS, 2019-2025
32 companies · $23.56 in 2025
The $23.56 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $240 · 2021: $371 · 2022: $419 · 2023: $533 · 2024: $441 · 2025: $23.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $291.69 | 2019-2024 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $208.30 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $166.16 | 2020-2024 | Airsupra |
| Novo Nordisk INC | $157.16 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $135.01 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $125.02 | 2021-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $122.77 | 2021-2023 | Myrbetriq, Veozah |
| Exact Sciences Corporation | $120.48 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $111.05 | 2019-2022 | |
| Pfizer INC. | $104.45 | 2021-2024 | |
| Abbvie INC. | $96.94 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.41 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $66.23 | 2021-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $50.48 | 2020-2023 | Gardasil 9 |
| Sumitomo Pharma America, INC. | $50.47 | 2023-2024 | Gemtesa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.84 | 2021-2022 | |
| Boston Scientific Corporation | $39.08 | 2022-2023 | Spectra Wavewriter |
| Avanir Pharmaceuticals, INC. | $35.85 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $29.12 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $27.74 | 2023 | |
| Janssen Pharmaceuticals, INC | $24.61 | 2019 | |
| Antares Pharma, INC. | $22.08 | 2023 | Xyosted, Tlando, Nocdurna |
| Xeris Pharmaceuticals, INC. | $20.84 | 2022 | |
| Amarin Pharma, INC. | $18.58 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.93 | 2024 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $16.55 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.04 | 2019 | |
| Eisai INC. | $15.10 | 2021 | |
| Almatica Pharma LLC | $14.29 | 2021 | |
| Edwards Lifesciences Corporation | $13.91 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Mylan Specialty L.P. | $13.67 | 2019 | |
| Shire North American Group INC | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.